Aktuellt
SENASTE
Redeye gives an additional comment on yesterday’s interim data in Vicore’s phase II IPF study. While early and indicative, we find the results very encouraging and potentially game-changing if replicated in the final study (and subsequent phase IIb and III studies). We slightly increase our already aggressive LoA and raise our base case to SEK 64 (62).
LÄS MER
